منابع مشابه
Pharmacoeconomics 2009;
Cost-effectiveness analysis (CEA) represents the most important tool in the health economics literature to quantify and qualify the reasoning behind the optimal decision process in terms of the allocation of resources to a given health intervention. However, the practical application of CEA in the regulatory process is often limited by some critical barriers, and decisions in clinical practice ...
متن کاملPharmacoEconomics 2011;
Bortezomib, thalidomide and lenalidomide can be aimed at treating patients with newly diagnosed multiple myeloma (both eligible and ineligible for transplantation) as well as those with relapsed or refractory disease. This review analysed the available clinical and economic data on these three drugs. Irrespective of which of the three agents is considered, the magnitude of the benefit in newly ...
متن کاملPharmacoeconomics of thrombosis management.
Venous thromboembolism (VTE) is the cause of significant morbidity and mortality and may lead to other complications, including recurrent VTE and long-term postthrombotic syndrome. Venous thromboembolism represents a huge health economic burden of nearly 500 million dollars/year in the United States. Without adequate prophylaxis, patients undergoing major orthopedic surgery are at high risk of ...
متن کاملPharmacoeconomics: a Review
‘Pharmacoeconomics’ is a new (and not altogether elegant) word; but economic interest in drug and other treatments of health problems is much older. Pharmacoeconomics is a sub-discipline of the field of health economics, which itself is a relatively new sub-discipline of economics, only formerly appearing in the economics scientific literature since the 1960s. Pharmacoeconomics is the descripti...
متن کاملPharmacoeconomics in pediatric asthma.
I n Canada throughout the 1990s, inhaled corticosteroids (ICS) have been the treatment of choice, and we continue to view ICS as the mainstay of treatment for persistent asthma in children, except for those whose disease is so mild that they only require infrequent, as-needed 2-agonist treatment.1 Corticosteroid dosage should continue to be individualized, and the minimum effective dose should ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Pharmaceutical and Biological Sciences
سال: 2020
ISSN: 2320-1924
DOI: 10.18231/j.jpbs.2020.005